1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

AI-Generated Plain Language Summaries Of Trial Results Can Save Time, But Need A Human Touch

 
• By Lauren Nardella

Staburo’s Kathi Künnemann examined the utility of artificial intelligence in developing plain language summaries for clinical trials results.

Artificial Intelligence Content Generator. A man uses a laptop to interact with AI assistant. AI offers functions like chatbot, generate images, write code, writer bot, translate and advertising. LLM.
AI in medical writing can be a significant time saving tool. (Shutterstock)
Key Takeaways
  • A case study by Staburo’s senior disclosure manager shows AI-generated plain language summaries of trial results, when reviewed by a medical writer, can match the quality of those created solely by a medical writer.
  • Using AI can significantly reduce the time required to create these summaries, aiding compliance with EU Clinical Trials Regulation, but AI outputs can be unreliable and require human correction.
  • Non-medical volunteers found both AI-assisted and human-only summaries to be of similar quality.

Plain language summaries of clinical trial results created with the help of the generative artificial intelligence tool, ChatGPT, and reviewed by a medical writer can achieve the same quality standards...

The findings highlight the potential benefits of using AI in clinical trial compliance processes but also emphasize the need for human supervision.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

 
• By Derrick Gingery

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.

More from Geography

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.